AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03970928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
Study NCT03692390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study NCT01957176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (ELT)
Description: Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
Study NCT00336245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T Intrauterine Contraceptive Device
Study NCT00336245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal Contraception
Study NCT01841476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Study NCT04053920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Load Resistance exercise
Description: leg extension, leg press, leg curl and calf press
Study NCT04053920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Load Resistance exercise
Description: leg extension, leg press, leg curl and calf press
Study NCT01167322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-07 for oral administration
Description: NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
Study NCT00291980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-AS02V vaccine
Description: HB-AS02V (20µg HBsAg) will be administered at Month 0
Study NCT00291980 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVAXPRO vaccine
Description: HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
Study NCT03822065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: 80 mg oral tablet single dose
Study NCT01195792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
Study NCT01195792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for up to 35 days and subjects will be assessed weekly
Study NCT03282630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion acupuncture
Description: * active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
Study NCT03282630 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sphenopalatine ganglion acupuncture
Description: * active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
Study NCT01629979 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB treatment
Description: the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
Study NCT01228188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted ILM Repositioning
Description: Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
Study NCT04042012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: soleus eccentric exercise
Study NCT04042012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE
Description: the application of galvanic current
Study NCT04042012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: soleus eccentric exercise and PNE
Study NCT00498225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus TS-1
Description: Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
Study NCT00498225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
Study NCT00498225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
Study NCT02088541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor oral tablet.
Study NCT03345901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally BID - twice daily
Study NCT04209712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haploid allogeneic NK cell therapy
Description: NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
Study NCT00722046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 0.1 mg/kg
Description: 0.1 mg/kg every 60 days (10 doses total)
Study NCT00722046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 0.5 mg/kg
Description: 0.5 mg/kg every 60 days (10 doses total)
Study NCT02088541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Study NCT02088541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: Ara-C Subcutaneous Injection.
Study NCT00722046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 1 mg/kg
Description: 1 mg/kg every 60 days (10 doses total)
Study NCT00722046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 60 days (10 doses total)
Study NCT03674086 — intervention group
Intervention type: DEVICE
Intervention: eAdjust 0.2 hearing aid smartphone application (or app)
Description: The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
Study NCT00440544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen in BCG naive subjects
Study NCT00440544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
Study NCT00440544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 50 ug H1 antigen in BCG immunized subjects
Study NCT02533778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
Study NCT04397796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-Allo.MSC
Description: BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
Study NCT04397796 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plasmalyte and human albumin
Study NCT02015806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RxTimerCap
Description: The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
Study NCT00440544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
Study NCT00440544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen in BCG immunized subjects
Study NCT00440544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
Study NCT03222583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet for oral administration
Study NCT03222583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration
Study NCT00722046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 3 mg/kg
Description: 3 mg/kg every 60 days (10 doses total)
Study NCT00722046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 8.5 mg/kg
Description: 8.5 mg/kg every 60 days (10 doses total)
Study NCT00402896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 300 mg/day orally for 10 weeks.
Study NCT04048044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to GHz electromagnetic energy (RejuvaMatrix)
Description: 75 decibels of 54 to 78 GHz daily for 60 minutes
Study NCT03239912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Description: Functional treatment will be achieved using the Twin-block appliance
Study NCT03239912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Functional treatment will be combined with low-level laser therapy on the TMG region
Study NCT02015806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take-N-Slide
Description: The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
Study NCT03039244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
Study NCT03039244 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
Study NCT03039244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Study NCT02015806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillbox
Description: The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
Study NCT02578472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.
Study NCT02578472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Study NCT02578472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.
Study NCT00971633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
Study NCT00971633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO
Study NCT00971633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
Study NCT01343420 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog Hair Extract, ALK-Abelló, Inc.
Description: ALK-Abelló dog epithelial 1:10w/v glycerin
Study NCT04545060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-7831 (sotrovimab)
Description: VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
Study NCT02089763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated recombinant human arginase
Study NCT03844152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented whey concentrate
Description: The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
Study NCT03348722 — intervention group
Intervention type: OTHER
Intervention: Active surveillance
Description: PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
Study NCT03348722 — intervention group
Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy (open, laparoscopic or robotic)
Study NCT03348722 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: External radical radiotherapy or brachitherapy
Study NCT03348722 — intervention group
Intervention type: PROCEDURE
Intervention: Other radical treatments
Description: High intensity focal ultrasound, cryotherapy, others
Study NCT03594500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PockeTalker
Description: The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
Study NCT01400074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib, Imatinib
Description: Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
Study NCT03753815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19G FNA needle
Description: Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
Study NCT03753815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20G FNB needle
Description: Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
Study NCT03942146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information on smoking cessation
Description: Smoking cessation is recommended 6 weeks before and after surgery
Study NCT02738762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutamine supplementation
Description: glutamine supplementation guided by glutamine levels in plasma
Study NCT04606368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage FLX
Description: Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
Study NCT06318221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental (Immunonutrition) Group
Description: Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group.
Study NCT06318221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Group ( Standard enteral nutrition)
Description: Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group.
Study NCT04436588 — intervention group
Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study NCT00055848 — intervention group
Intervention type: GENETIC
Intervention: cytogenetic analysis
Study NCT00055848 — intervention group
Intervention type: GENETIC
Intervention: gene mapping
Study NCT00055848 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT04021316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dCELL® Human Dermis (decellularised dermal skin allograft - DCD)
Description: DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
Study NCT04021316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandaging therapy
Description: Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.